Text Size
Trial record 5 of 51 for:    Pompe Disease
Previous Study | Return to List | Next Study

Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease

This study has been completed.
Sponsor:
Information provided by:
Genzyme
ClinicalTrials.gov Identifier:
NCT00113035
First received: June 3, 2005
Last updated: July 16, 2007
Last verified: December 2005
History of Changes
  Purpose

Pompe disease (also known as glycogen storage disease type II) is caused by a deficiency of a critical enzyme in the body called acid alpha-glucosidase (GAA). Normally, GAA is used by the body's cells to break down glycogen (a stored form of sugar) within specialized structures called lysosomes. In patients with Pompe disease, an excessive amount of glycogen accumulates and is stored in various tissues, especially heart and skeletal muscle, which prevents their normal function. The primary objective of this study is to identify potential candidates for future clinical studies in Pompe disease.


Condition
Pompe Disease

Study Type: Observational
Study Design: Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Time Perspective: Prospective
Official Title: Screening Protocol to Evaluate Acid Alpha Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease for Potential Inclusion in Future Clinical Studies With Myozyme (Alglucosidase Alfa)

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Genzyme:

Estimated Enrollment: 60
Study Start Date: May 2005
Estimated Study Completion Date: September 2005
  Eligibility

Ages Eligible for Study:   8 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must provide written informed consent prior to any study-related procedures being performed
  • Clinical presentation consistent with late-onset Pompe disease, or a current clinical diagnosis of late-onset Pompe disease
  • Must be greater than or equal to 8 years of age
  • Must be able to ambulate (use of assistive devices, such as a walker, cane or crutches, is permitted)

Exclusion Criteria:

  • Requires the use of invasive ventilatory support
  • Requires the use of noninvasive ventilatory support while awake and in an upright position
  • Use of any investigational product within 30 days prior to study enrollment
  • Unwillingness to comply with protocol requirements
  • Has clinically significant organic disease, unstable medical condition, serious or intercurrent illness
  • Is pregnant or lactating
  • Has participated in the Prospective Observational Study in Patients with Late-Onset Pompe Disease (AGLU02303, “LOPOS”)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00113035

Locations
United States, California
Tower Hematology/Oncology Medical Group
Beverly Hills, California, United States, 90211
United States, District of Columbia
Children's National Medical Center
Washington, District of Columbia, United States, 20010
United States, Missouri
Washington University Medical Center
St. Louis, Missouri, United States, 63110
United States, New York
Mount Sinai School of Medicine
New York, New York, United States, 10029
United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
Genzyme
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00113035     History of Changes
Other Study ID Numbers: AGLU02905
Study First Received: June 3, 2005
Last Updated: July 16, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Genzyme:
Glycogen Storage Disease Type II
GSD-II
Pompe Disease
Pompe Disease (Late-Onset)
 Glycogen Storage Disease Type II (GSD-II)
Acid Maltase Deficiency
Glycogenosis 2

Additional relevant MeSH terms:
Glycogen Storage Disease Type II
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
 Genetic Diseases, Inborn
Glycogen Storage Disease
Lysosomal Storage Diseases
Metabolic Diseases
Metabolism, Inborn Errors
Carbohydrate Metabolism, Inborn Errors

ClinicalTrials.gov processed this record on May 16, 2013